Bavarian Nordic AS of Denmark hopes to de-risk planned Phase III studies of its MVA-BN RSV prophylactic vaccine by first running a human challenge trial in collaboration with contract research organization SGS to generate better efficacy data for the therapy, the Danish group's CEO told Scrip.
The planned human challenge – or the controlled human infection model – would be conducted in parallel with the Danish...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)